Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Nefazodone: a new antidepressant

V L Ellingrod1, P J Perry

  • 1College of Pharmacy, University of Iowa, Iowa City 52242-0123, USA.

American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists
|December 15, 1995
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Aberrant Brain Signal Variability and COMT Genotype in Chronic TMD Patients.

Journal of dental research·2021
Same author

Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update.

Clinical pharmacology and therapeutics·2016
Same author

An 11-year retrospective review of venlafaxine ingestion in children from the California Poison Control System.

Human & experimental toxicology·2015
Same author

Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants.

Clinical pharmacology and therapeutics·2013
Same author

The influence of the brain-derived neurotropic factor Val66Met genotype and HMG-CoA reductase inhibitors on insulin resistance in the schizophrenia and bipolar populations.

Clinical and translational science·2012
Same author

The influence of metabolic syndrome, physical activity and genotype on catechol-O-methyl transferase promoter-region methylation in schizophrenia.

The pharmacogenomics journal·2012
Same journal

Recent and anticipated novel drug approvals (Q2 2026 through Q1 2027).

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·2026
Same journal

Optimizing transitions from direct factor Xa inhibitors to unfractionated heparin therapy.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·2026
Same journal

Impact of pharmacist involvement on hospital sepsis response teams.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·2026
Same journal

Attributes of centralized health-system specialty pharmacy clinics: A scoping review using the Donabedian model.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·2026
Same journal

Zoliflodacin: A novel single-dose oral antibiotic for uncomplicated urogenital gonorrhea.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·2026
Same journal

Implementation of a paid apprenticeship-model pharmacy technician training program.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·2026
See all related articles

Nefazodone hydrochloride, a novel antidepressant, effectively treats major depression by enhancing serotonin transmission and shows benefits for anxiety and sleep disturbances. It is as effective as imipramine with potentially fewer adverse drug reactions.

Area of Science:

  • Pharmacology and clinical medicine
  • Neuroscience
  • Psychiatry

Background:

  • Nefazodone hydrochloride is a novel antidepressant agent.
  • It exhibits a distinct pharmacological profile compared to its structural analogue, trazodone.

Purpose of the Study:

  • To describe the chemistry, pharmacology, pharmacokinetics, and clinical efficacy of nefazodone hydrochloride.
  • To evaluate its effectiveness and safety in treating major depression, anxiety, and sleep disturbances.

Main Methods:

  • Review of chemistry, pharmacology, pharmacokinetics, and clinical trial data.
  • Placebo-controlled trials comparing nefazodone to imipramine.
  • Analysis of adverse drug reactions (ADRs) and drug interactions.

Related Experiment Videos

Main Results:

  • Nefazodone enhances serotonin (5-hydroxytryptamine [5-HT]) synaptic transmission via 5-HT2 receptor antagonism and 5-HT reuptake inhibition, potentially enhancing 5-HT1A-mediated transmission.
  • It weakly inhibits norepinephrine reuptake.
  • Placebo-controlled trials demonstrated nefazodone's efficacy comparable to imipramine for major depression, with benefits in associated anxiety and sleep disturbances.
  • Common ADRs include asthenia, somnolence, and nausea; sexual dysfunction ADRs may be less frequent than with other antidepressants.
  • Nefazodone inhibits CYP3A4, necessitating caution with drugs metabolized by this enzyme (e.g., triazolam, midazolam) and contraindicating coadministration with terfenadine or astemizole.

Conclusions:

  • Nefazodone hydrochloride is an effective antidepressant comparable to imipramine.
  • It offers potential benefits in managing depression-related anxiety and sleep disturbances.
  • Nefazodone may present a favorable adverse drug reaction profile compared to other antidepressants, though drug interactions must be managed carefully.